Most Likely to Benefit From the Oral Option Have type 2 diabetes with inadequate glucose control on existing medicines Have established cardiovascular disease or high cardiovascular risk where the SOUL trial evidence directly applies Have a preference against injections needle phobia, dexterity issues, or simply a strong preference for tablets Have modest weight loss goals the oral form produces meaningful but more moderate weight reduction than higher-dose injectables Can reliably maintain the strict morning fasting routine patients whose mornings are very variable may find the once-weekly injectable more practical Are being considered for injectable GLP-1 therapy but want to trial the class first oral semaglutide can be a useful introduction Side Effects The side effect profile of oral semaglutide is similar to the injectable form, gastrointestinal symptoms are the most common experience, particularly in the early weeks of treatment

For individuals using anabolic steroids non-medically, harm reduction services are available through some NHS trusts and specialist clinics
References: International Study of Asthma and Allergies in Childhood (ISAAC) Acetaminophen and Asthma Risk Glutathione Depletion & Acetaminophen in Asthma Risk
Beech RD, Lowthert L, Leffert JJ, Mason PN, Taylor MM, Umlauf S, et al
The biggest mistake is treating appetite reduction as the whole plan